Cancer clinical trials in the region Bourgogne-Franche-Comté

206 currently recruiting clinical trials
Region Bourgogne-Franche-Comté
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Lymphoma #NCT06284122 #2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min < 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3 Multiple myeloma #NCT06918002 #2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06819007 #2024-516982-35-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3 Thyroid and adrenal gland cancer #NCT04290663 #2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3 Thyroid and adrenal gland cancer #NCT03583710
Required histologic types
Adrenal gland cancer
Required histologic sub types
Adrenocortical carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy Mitotane
10 recruiting sites
M.D. Anderson Cancer Center
Phase 3 Breast cancer #NCT06966700
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative HR Positive
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy Hormone therapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT05918302 #2022-502154-13-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2
8 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos